В ДРК начались первые клинические испытания препаратов от редкого штамма Эбола Бундибугьо

On July 6, 2026, patients with Ebola virus Bundibugyo strain in the Democratic Republic of the Congo began receiving experimental drugs as part of a clinical trial. This is the first systematic attempt to test treatment specifically against this rare strain — the current outbreak has claimed the lives of over 100 people; the total death toll from Ebola in the DRC has exceeded 500.

What is the Bundibugyo strain?

Bundibugyo is one of the rarest known types of Ebola virus. It was first identified in 2007 in the Bundibugyo district of western Uganda and since then has caused only isolated outbreaks, primarily in Uganda and the DRC. Unlike the Zaire strain — responsible for the largest epidemics, including the 2014–2016 outbreak with more than 11,000 deaths — Bundibugyo remains poorly understood.

The small number of documented cases long prevented comprehensive clinical research. As a result, there are no approved drugs specifically developed for this strain: doctors have used drugs developed against other Ebola variants without solid evidence of their effectiveness.

Why conduct trials during an active outbreak?

This is a forced, but standard global practice for rare infections: gathering a sufficient number of participants for statistically significant results is objectively possible only when the disease is actively spreading.

Key facts about the current situation:

• Clinical trials began on July 6, 2026, in the Democratic Republic of the Congo
• The death toll from the current outbreak has exceeded 100 people
• In total, more than 500 people have died from Ebola in the DRC
• The trial is specifically targeting the Bundibugyo strain — for the first time in the history of observations

In parallel with the trials, quarantine measures and contact tracing of infected individuals continue. Work in remote areas with limited medical infrastructure remains a serious operational challenge.

What this means

The launch of the first clinical trial against the Bundibugyo strain is a long-awaited step for tropical infection specialists. Even if specific drugs do not produce an immediate effect, the accumulated data will lay a scientific foundation for combating future outbreaks of this rare but deadly virus.